Lung Therapeutics

Lung Therapeutics is a privately held, clinical stage pharmaceutical company based in Austin, Texas that was founded in 2013 by Andrew Mazar and Steven Idell. It's pursues orphan drug indications for lung injury and disease due to fibrosis for which there are no effective non-surgical options.

The company has two lead product candidates in its pipeline, LTI-01 and LTI-03. They focus on loculated plural effusion and idiopathic pulmonary fibrosis, respectively.

LTI-01 is an injectable, fibrinolytic drug that maximizes scar removal around the lung and thereby promotes fluid drainage while minimizing bleeding risk and other complications. Its active pharmaceutical ingredient is a proenzyme, or zymogen, which slowly becomes activated in the pleural space surrounding the lungs. LTI-01 has received orphan drug designation from both the FDA (2014) and the European Commission (2015) for the treatment of empyema. Phase 1B clinical trials are being conducted at three sites in Australia and New Zealand.

LTI-03 is a drug product that addresses Idiopathic Pulmonary Fibrosis. It is in preclinical development and has shown to resolve bleomycin-induced lung injury. It also has the potential to restore healthy lung function in patients suffering from the disease. In addition, LTI-03 has shown promise in other models of fibrotic diseases.

On September 30, 2015 Lung Therapeutics completed their series A funding with $2.6 million in funding from UT Horizon Fund.

On June 6, 2017 Lung Therapeutics completed their series B funding round with $14.3 million in funding from Bios Partners (lead investor) and UT Horizon Fund.